Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.
about
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDPhosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemiap70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.SYK regulates mTOR signaling in AML.Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) CellsSingle-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.Phospho-specific flow: fixating on the target.Phenotypically Dormant and Immature Leukaemia Cells Display Increased Ribosomal Protein S6 PhosphorylationA phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancerThe oncogene eIF4E: using biochemical insights to target cancer.Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cellsAcute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.The Modification of Tet1 in Male Germline Stem Cells and Interact with PCNA, HDAC1 to promote their Self-renewal and Proliferation.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Application of molecular technologies for phosphoproteomic analysis of clinical samples.Mass spectrometry-driven phosphoproteomics: patterning the systems biology mosaic.Implementation of highly sophisticated flow cytometry assays in multicenter clinical studies: considerations and guidance.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Single-cell proteomics: potential implications for cancer diagnostics.Phosphorylation of nuclear and cytoplasmic pools of ribosomal protein S6 during cell cycle progression.Effect of confounding factors on a phospho-flow assay of ribosomal S6 protein for therapeutic drug monitoring of the mTOR-inhibitor everolimus in heart transplanted patients.Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress.Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season.Effect of CAL-101, a PI3Kδ inhibitor, on ribosomal rna synthesis and cell proliferation in acute myeloid leukemia cells.Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells.
P2860
Q27852087-A314C4ED-D2CB-406E-A3DC-937ABA14B6FAQ28547880-9FB19E7F-E843-4C5F-8082-7165FD841E7AQ30371561-22EE1D53-FC29-4769-8FC2-229DCD285388Q33641643-C9EA9606-A075-454E-9151-F5AF022F3FA7Q33882022-B17DD7C6-4D35-4317-9F6B-E0A4BE3112EEQ35300118-238C2931-128A-43C2-8EB3-DF74AE069C4FQ35836410-EF82E9EE-6748-458D-A78B-E69C4B3D2958Q35960603-AD571152-E364-42CF-9F9C-2C2121EA2B1FQ35987564-49E4F079-10C3-4B35-823D-FE2F7E77C35AQ36200159-6B5806FD-2968-4606-BF1E-883EF61F58A8Q36842143-0BBAB5C0-D1C4-4303-8E77-A89A3BD87CA4Q37046021-18657B0E-4799-488B-A1A0-0A2BF5CE8C77Q37132224-1FCF7BAF-1B8E-4B14-B17A-85CEB8A99BFAQ37364509-0EDA8F25-458C-430E-8854-1228079D3175Q37421905-782B3E6A-6B05-4CA5-8945-177BC9E810C6Q37643136-9A0C50A1-DE62-475C-A549-96DA9FA5A172Q38194417-D330F641-2DB1-4589-9582-171E43AE8054Q38217990-0EFC2EE8-DE5D-4D3F-9045-24E02B4C1B38Q38516622-FECA7911-D863-4A8D-8051-F80D454AB067Q38521775-26FA488B-D954-4D96-B508-C7C7E4B45B7FQ38741203-A3A252D4-0437-4771-8C73-B96358212C78Q39223292-4D5D4AB9-A376-4D20-A781-577ED8378E0DQ39570274-2ED065C8-5DFC-4CDB-8652-7979B6D2CD3BQ40240966-2EF91DBB-7C74-4DF0-848B-44B2EEC9098BQ41965978-3ABC98D4-9D5E-480A-AEB3-16A7FA94F25DQ42774255-A3950AA8-9766-4F87-9568-132D5B09BE71Q42974476-EDAFB586-547D-4731-A7B2-B72E56298680Q44018556-D76135DA-814E-4954-85DF-D483236D7908Q45731131-6B4EA1B2-37BE-4DEB-B19B-10801132C3E3Q50285730-2B01BF36-B366-4CDE-B8A0-C3AF8AC3C2A2Q52334917-9DFE3296-AADB-45FD-83B0-449D70730BC4Q54979826-CC5024BB-CE62-4D18-A9C2-20E055FE7FCC
P2860
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Single-cell pharmacodynamic mo ...... us and intensive chemotherapy.
@ast
Single-cell pharmacodynamic mo ...... us and intensive chemotherapy.
@en
type
label
Single-cell pharmacodynamic mo ...... us and intensive chemotherapy.
@ast
Single-cell pharmacodynamic mo ...... us and intensive chemotherapy.
@en
prefLabel
Single-cell pharmacodynamic mo ...... us and intensive chemotherapy.
@ast
Single-cell pharmacodynamic mo ...... us and intensive chemotherapy.
@en
P2093
P2860
P1476
Single-cell pharmacodynamic mo ...... us and intensive chemotherapy.
@en
P2093
Alexander E Perl
Doris Shank
Margaret T Kasner
Martin Carroll
Selina M Luger
P2860
P304
P356
10.1158/1078-0432.CCR-11-2346
P407
P577
2011-12-13T00:00:00Z